Malaria Clinical Trial
Official title:
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Malaria is one of the major infectious diseases in the world with a tremendous impact on the
quality of life, significantly contributing to the ongoing poverty in endemic countries. It
causes 800.000 deaths per year, the majority of which are children under the age of five.
The malaria parasite enters the human body through the skin, by the bite of an infected
mosquito. Subsequently, it invades the liver and develops and multiplies inside the
hepatocytes. After a week, the hepatocytes burst open and the parasites are released in the
blood stream, causing the clinical phase of the disease.
As a unique opportunity to study malaria immunology and efficacy of immunisation strategies,
a protocol has been developed in the past to conduct controlled human malaria infections
(CHMIs). CHMIs generally involve small groups of malaria-naïve volunteers infected via the
bites of P. falciparum infected laboratory-reared Anopheline mosquitoes. Although
potentially serious or even lethal, P. falciparum malaria can be radically cured at the
earliest stages of blood infection when risks of complications are virtually absent.
The investigators have shown previously that healthy human volunteers can be protected from
a malaria mosquito (sporozoite) challenge by immunization with sporozoites (by mosquito
bites) under chloroquine prophylaxis (CPS immunization). Interestingly, sterile protection
in 100% of the human CPS immunized volunteers was achieved by a relatively miniscule dose,
i.e. a total of 45 infectious mosquito bites, strikingly 20-fold more potent than the 1000
bites needed in a model using irradiated mosquitoes. One possible explanation for this
efficient induction of protective immunity, is the immune modulating effect of chloroquine.
The investigators aim to assess this possible immune modulating effect in CPS immunization
by comparing immunization with P. falciparum sporozoites under chloroquine with immunization
under mefloquine prophylaxis, which has the same antimalarial effect, but not the immune
modulating effects known from chloroquine.
Status | Completed |
Enrollment | 20 |
Est. completion date | April 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: 1. Age > 18 and < 35 years healthy volunteers (males or females) 2. Good health based on history and clinical examination 3. Negative pregnancy test 4. Use of adequate contraception for females 5. Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study 6. Agreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study 7. Willingness to undergo a Pf controlled infection through mosquito bites 8. Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till treatment is finished) 9. Reachable (24/7) by mobile phone during the whole study period 10. Available to attend all study visits 11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period 12. Willingness to undergo HIV, hepatitis B and hepatitis C tests 13. Negative urine toxicology screening test at screening visit and the day before challenge 14. Willingness to take a prophylactic regime of chloroquine or mefloquine and curative regimen of Malarone® Exclusion Criteria: 1. History of malaria 2. Plans to travel to malaria endemic areas during the study period 3. Plans to travel outside of the Netherlands during the challenge period 4. Previous participation in any malaria vaccine study and/or positive serology for Pf 5. Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers 6. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) 7. History of arrhythmias or prolonged QT-interval 8. Positive family history in 1st and 2nd degree relatives for cardiac events < 50 years old 9. An estimated, ten year risk of fatal cardiovascular disease of =5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system 10. Clinically significant abnormalities in electrocardiogram (ECG) at screening 11. Body Mass Index (BMI) below 20 or above 30 kg/m2 12. Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis 13. Positive HIV, HBV or HCV tests 14. Participation in any other clinical study within 30 days prior to the onset of the study 15. Enrollment in any other clinical study during the study period 16. For women: pregnancy or lactation 17. Volunteers unable to give written informed consent 18. Volunteers unable to be closely followed for social, geographic or psychological reasons 19. History of drug or alcohol abuse interfering with normal social function 20. A history of treatment for psychiatric disease or moderate or severe psychological episode in volunteer 21. A history of convulsions in volunteer 22. Severe depression, anxiety disorder of psychosis in first or second degree family 23. Contra-indications to Malarone®, chloroquine or mefloquine including hypersensitivity or treatment taken by the volunteer that interferes with Malarone®, chloroquine or mefloquine 24. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids and oral anti-histaminic are allowed) and during the study period 25. Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia 26. Co-workers or trainees of the departments of Medical Microbiology, Parasitology, or Internal Medicine of the Leiden University medical Centre 27. A history of sickle cell anemia, sickle cell trait, thalassemia, thalassemia trait or G6PD deficiency |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Netherlands | Leiden University Medical Centre | Leiden |
Lead Sponsor | Collaborator |
---|---|
Radboud University | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of prepatent period after challenge infection as measured by microscopy | 21 days after challenge (day 239 of the study) | No | |
Secondary | Development of parasitemia as measured by PCR | 21 days after challenge (day 239 of study) | No | |
Secondary | Frequency of signs or symptoms in study groups | Day 0 - day 358 of study | Yes | |
Secondary | Cellular immune responses between study groups | Day 0 -day 358 of study | No | |
Secondary | Humoral immune responses between study groups | Day 0 - 358 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |